First-Line Crizotinib in ALK-Positive Lung Cancer

被引：0
|
作者：
Tural, Deniz [1 ]
Kilickap, Saadettin [2 ]
机构：
[1] Akdeniz Univ, Sch Med, TR-07058 Antalya, Turkey
[2] Hacettepe Univ, Inst Canc, Ankara, Turkey
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2015年 / 372卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：781 / 781
页数：1
相关论文
共 50 条
  • [21] Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers
    Chuang, Jody C.
    Neal, Joel W.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (05) : 639 - 641
  • [22] Taiwan Nationwide Study of First-Line ALK-TKI Therapy in ALK-Positive Lung Adenocarcinoma
    Zheng, Zhe-Rong
    Wu, Jia-Jun
    Chiang, Chun-Ju
    Chen, Tzu-, I
    Chen, Kun-Chieh
    Chu, Cheng-Hsiang
    Lin, Sheng-Yi
    Yu, Sung-Liang
    Lee, Wen-Chung
    Liu, Tsang-Wu
    Chang, Gee-Chen
    TARGETED ONCOLOGY, 2024, 19 (06) : 941 - 955
  • [23] Cost Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer
    Djalalov, Sandjar
    Beca, Jaclyn
    Hoch, Jeffrey S.
    Krahn, Murray
    Tsao, Ming-Sound
    Cutz, Jean-Claude
    Leighl, Natasha B.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (10) : 1012 - +
  • [24] An update on Alectinib: a first line treatment for ALK-positive advanced lung cancer
    Zhou, Yourong
    Yin, Yiming
    Xu, Jiangxin
    Xu, Zhifei
    Yang, Bo
    He, Qiaojun
    Luo, Peihua
    Yan, Hao
    Yang, Xiaochun
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (12) : 1361 - 1373
  • [25] Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Cruz, Barbara D.
    Barbosa, Mariana M.
    Torres, Lucas L.
    Azevedo, Pamela S.
    Silva, Vania E. A.
    Godman, Brian
    Alvares-Teodoro, Juliana
    ONCOLOGY AND THERAPY, 2021, 9 (02) : 505 - 524
  • [26] Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Barbara D. Cruz
    Mariana M. Barbosa
    Lucas L. Torres
    Pamela S. Azevedo
    Vânia E. A. Silva
    Brian Godman
    Juliana Alvares-Teodoro
    Oncology and Therapy, 2021, 9 : 505 - 524
  • [27] J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer
    Gainor, Justin F.
    Shaw, Alice T.
    LANCET, 2017, 390 (10089): : 3 - 4
  • [28] Successful Desensitization of Two Patients with ALK-Positive Lung Cancer and Hypersensitivity to Crizotinib
    Awad, Mark M.
    Lax, Timothy P.
    Slawski, Benjamin R.
    Shaw, Alice T.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (11) : 1726 - 1728
  • [29] Crizotinib Response in a Late Relapse of ALK-positive Lung Adenocarcinoma
    Zito Marino, Federica
    Morabito, Alessandro
    Gridelli, Cesare
    Rocco, Gaetano
    Liguori, Giuseppina
    De Rosa, Nicla
    Botti, Gerardo
    Franco, Renato
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2016, 24 (09) : E86 - E88
  • [30] Updated analyses from the CROWN study of first-line lorlatinib vs crizotinib in Asian patients with ALK-positive non-small cell lung cancer (NSCLC)
    Qing, Z.
    Kim, H. R.
    Soo, R. A.
    Chiu, C. H.
    Hayashi, H.
    Kim, S-W.
    Teraoka, S.
    Kim, D-W.
    Zhan, H.
    Zhao, H.
    Li, H.
    Mok, T. S. K.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1007 - S1007
12345